Meda expands fentanyl deal with BDSI

12 January 2009

Swedish specialty pharmaceutical company Meda has expanded its deal to acquire worldwide rights to the drug Onsolis (fentanyl buccal soluble  film, formerly BEMA Fentanyl), a treatment for breakthrough pain in  opioid tolerant patients with cancer, from collaboration partner  USA-based BioDelivery Sciences).

The transaction will give Meda exclusive rights to distribute Onsolis in  all countries except Taiwan and South Korea for a one-time cash payment  of $3.0 million. Meda will also provide a further $3.0 million advance  on the anticipated aggregate $30.0 million milestone following US Food  and Drug Administration approval for the drug, which is anticipated  during the second quarter of this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight